Recombinant human erythropoietin and overall survival in cancer patients: Results of a comprehensive meta-analysis

Journal of the National Cancer Institute

Volumn 97, Issue 7, 2005, Pages 489-498

  Bohlius, Julia ^a   Langensiepen, Simon ^a   Schwarzer, Guido ^b   Seidenfeld, Jerome ^c   Piper, Margaret ^c   Bennett, Charles ^d   Engert, Andreas ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Blue Cross and Blue Shield Association   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT;

ANEMIA; BIBLIOGRAPHIC DATABASE; BLEEDING; CALCULATION; CANCER; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG USE; EMBASE; ERYTHROCYTE TRANSFUSION; EXPERIMENTAL DESIGN; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; PRURITUS; PUBLISHING; REGRESSION ANALYSIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY ANALYSIS; SKIN IRRITATION; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TUMOR GROWTH; BLOOD TRANSFUSION; CONTROLLED CLINICAL TRIAL; NEOPLASM; RANDOMIZED CONTROLLED TRIAL; STATISTICS; SURVIVAL; TREATMENT OUTCOME;

ANEMIA; BLOOD TRANSFUSION; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 15944374753     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji087     Document Type: Review

References (74)

1. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004;116(Suppl. 7A):11S-26S.
2. Engert A. Recombinant human erythropoietin as an alternative to blood transfusion in cancer-related anaemia. Disease Management and Health Outcomes 2000;8:259-72.
3. Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004;15:979-86.
4. Frommhold H, Guttenberger R, Henke M. The impact of blood hemoglobin content on the outcome of radiotherapy. Strahlentherapie und Onkologie 1998;174(Suppl IV):31-4.
5. Hockel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45-50.
6. Knocke TH, Weitmann HD, Feldmann HJ, Selzer E, Potter R. Intratumoral pO2 measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 1999;53:99-104.
7. Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50:705-15.
8. Silver DF, Piver MS. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol Oncol 1999;73:280-4.
9. Antonadou D, Cardamakis E, Puglisi M, Malamos N, Throuvalas N. Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. Final results of a randomized phase III study. Eur J Cancer 2001;37(Suppl. 6):S144.
10. Henke M, Laszig R, Ruebe C, Schaefer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
11. Leyland-Jones B; BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-60.
12. Goodnough LT. Risks of blood transfusion. Crit Care Med 2003;31 (12 Suppl):S678-86.
13. Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, et al. Comparative pharmacokineics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991;50:702-12.
14. Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B. Epoetin alfit and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998;100:79-89.
15. Joy MS. Darbepoetin alfa: a novel erythropoiesis-stimulating protein. Ann Pharmacother 2002;36:1183-92.
16. Heatherington AC, Schuller J, Mercer AJ. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. Br J Cancer 2001;84(Suppl 1):11-6.
17. Hellstrom Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995;89:67-71.
18. Quirt I, Micucci S, Moran LA, Pater J, Browman G. The role of erythropoietin in the management of cancer patients with non-hematologic malignancies receiving chemotherapy. Cancer Care Ontario Practice Guidelines Initiative 2003.
19. Bottomley A, Thomas R, van Steen K, Flechtner H, Djulbegovic; B. Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about? Lancet Oncol 2002;3:145-53.
20. Clark O, Adams JR, Bennett CL, Djulbegovic B. Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer 2002;2:23.
21. Aronson N, Seidenfeld J, Piper MA, Flamm C, Hasselblad V, Ziegler KM. Uses of erythropoietin for anemia in oncology. Evidence report/technology assessment No. 30 Prepared by the Blue Cross and Blue Shield Association Evidence-based Practice Center 2001; Contract No. 290-97-0015. AHRQ Publ No. 01-E009. Rockville (MD): Agency for Healthcare Research and Quality.
22. Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett CL, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001;93:1204-14.
23. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett CL, et al. Erythropoietin for patients with malignant disease. The Cochrane Database of Systematic Reviews 2004, Issue 3. Art No.: CD003407. DOI: 10.1002/14651858.CD003407.pub2.
24. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Computat Graph Stat 1996;5:299-314.
25. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34.
26. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999;319:1492-5.
27. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
28. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999;18:2693-708.
29. Akaike H. Fitting autoregressive models for prediction. Ann Inst Stat Math 1969;21:243-7.
30. Osterborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-94.
31. Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. Blood 1996;87:2675-82.
32. Ten Bokkel Huinink WW, De Swart CA, Van Toorn DW, Morack G, Breed WP, Hillen HF, et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 1998;15:174-82.
33. Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller Ziegler L, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995;86:4446-53.
34. Henke M, Guttenberger R, Barke A, Pajonk F, Potter R, Frommhold H. Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiother Oncol 1999;50:185-90.
35. Kunikane H, Watanabe K, Fukuoka M, Saijo N, Furuse K, Ikegami H, et al. Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. Int J Clin Oncol 2001;6:296-301.
36. Thatcher N, De Campos ES, Bell DR, Steward WP, Varghese G, Morant R, et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 1999;80:396-402.
37. Carabantes FJ, Benavides M, Trujillo R, Cobo M, Hebrero ML, Garcia S, et al. Epoetin alfa in the Prevention of Anemia in Cancer Patients Undergoing Platinum-Based Chemotherapy (CT). A prospective randomized study [meeting abstract]. Proc ASCO 1999; abstract 2303.
38. Coiffier B, Boogaerts MC. Impact of epoetin beta versus standard care on quality of life in patients with malignant disease. 6th Congress of the European Haematology Association 2001; abstract 194.
39. Quirt I, Micucci S, Moran LA, Pater J, Browman G. The role of recombinant human erythropoietin (EPO) in reducing red blood cell transfusions and maintaining quality of life (QOL) in patients with lymphoma and solid tumors receiving cytotoxic chemotherapy. Results of a randomized, double-blind, placebo-controlled clinical trial. Blood 1996;88(Suppl 1):347a.
40. Rose E, Rai K, Revicki D, Brown R, Reblando J and the EPO in Anemia of CLL Study Group. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). Blood 1994;84(Suppl 1):526a.
41. Throuvalas NA, Antonadou D, Boufi M, Lavey R, Malamos N. Erythropoietin decreases transfusion requirements during radiochemotherapy. Proc ASCO 2000; Abstract 1558.
42. Abels R. Erythropoietin for anemia in cancer patients. Eur J Cancer 1993;29a(Suppl 2):2-8.
43. Cascinu S, Fedeli A, Del Ferro E, Fedeli SL, Catalano G. Recombinant Human Erythropoietin Treatment in Cisplatin-Associated Anemia: a randomized, double-blind trial with placebo. J Clin Oncol 1994;12:1058-62.
44. Case DC, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993;85:801-6.
45. Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 1997;15:2715-21.
46. Dunphy FR, Harrison BR, Dunleavy TL, Rodriguez JJ, Hilton JG, Boyd JH. Erythropoietin reduces anemia and transfusions. Cancer 1999;86:1362-7.
47. Henry DH, Brooks BJ Jr, Case DC Jr, Fishkin E, Jacobson R, Keller AM, et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am 1995;1:252-60.
48. Italian Cooperative Study Group. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 1998;103:1070-4.
49. Kurz C, Marth C, Windbichler G, Lahousen M, Medl M, Vavra N, et al. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol Oncol 1997;65:461-6.
50. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74.
51. Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 1998;9:255-60.
52. Thompson JA, Gilliland DG, Prchal JT, Bennett JM, Larholt K, Nelson RA, et al. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group. Blood 2000;95:1175-9.
53. Welch RS, James RD, Wilkinson PM. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer. Cancer J Sci Am 1995;1:261.
54. Wurnig C, Windhager R, Schwameis E, Kotz R, Zoubek A, Stockenhuber F, et al. Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). Transfusion 1996;36:155-9.
55. Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001;113:172-9.
56. Silvestris F, Romito A, Fanelli P, Vacca A, Dammacco F. Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol 1995;70:313-8.
57. Luksenburg H, Weir A, Wager R. Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy [monograph on the internet], FDA Briefing Document, May 4, 2004, Oncologic Drugs Advisory Committee [cited 2005 Jan 3). Available from http://www.fda.gov/ohrms/dockets/ac/04/briefing/ 4037B2_04_FDA-Aranesp-Procrit.htm
58. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90.
59. Becker A, Stadler P, Lavey RS, Hansgen G, Kuhnt T, Lautenschlager C, et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2000;46:459-66.
60. Henke M, Guttenberger R. Erythropoietin in radiation oncology - a review. Oncology 2000;58:175-82.
61. Kelleher DK, Thews O, Vaupel P. Can erythropoietin improve tumor oxygenation? Strahlentherapie und Onkologie 1998; 174(Suppl IV):20-3.
62. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561-5.
63. Acs G, Zhang PJ, Rebbeck TR, Acs P, Verma A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 2002;95:969-81.
64. Arcasoy MO, Amin K, Karayal AF, Chou SC, Raleigh JA, Varia MA, et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 2002;82:911-8.
65. Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003;24:1021 9.
66. Vaupel P, Mayer A. Letter. Lancet 2004;363:992.
67. Janecka IP. Letten Lancet 2004;363:993-4.
68. Rosen FR, Haraf DJ, Kies MS, Stenson K, Portugal L, List MA, et al. Multicenter randomized phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res 2003;9:1689-97.
69. Bamias A, Aravantinos G, Kalofonos C, Timotheadou N, Siafaka V, Vlahou I, et al. Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology 2003;64:102-10.
70. Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, et al. Phase III, randomized, double-blind study of epoetin alfa versus placebo in anemic patients with cancer undergoing chemotherapy. J Clin Oncol 2004;Sep 27 [Epub ahead of print].
71. Cirillo M, Capasso, G, DeSanto NG. Relationship between hematocrit and blood pressure: implications for primary hypertension. Nephron 1993;65:505-10.
72. Prabhakar SS, Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 1997;47:331-5.
73. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75.
74. Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, Mc Williams N, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351:1403-8.